Neurocrine Biosciences
NBIX
#1670
Rank
โ‚ฌ11.10 B
Marketcap
110,64ย โ‚ฌ
Share price
1.34%
Change (1 day)
0.91%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Operating Margin for Neurocrine Biosciences (NBIX)

Operating Margin at the end of 2025: 24.66%

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current Operating Margin is 24.66%. At the end of 2025 the company had an Operating Margin of 24.66%.

Operating Margin history for Neurocrine Biosciences from 2001 to 2025

Operating Margin at the end of each year

Year Operating Margin Change
202524.66%19.51%
202420.63%17.25%
202317.60%22.48%
202214.37%60.62%
20218.95%-12.31%
202010.20%72.9%
20195.90%22.12%
20184.83%-105.48%
2017-88.19%-90.62%
2016-940.60%109.1%
2015-449.84%
2013-1,578.97%-16797.76%
20129.46%-80.52%
201148.53%-304.06%
2010-23.78%-98.62%
2009-1,728.34%-22.47%
2008-2,229.26%-86.84%
2007-16,936.19%6098.17%
2006-273.25%1425.49%
2005-17.91%-66.61%
2004-53.65%147.89%
2003-21.64%-95.87%
2002-523.89%487.29%
2001-89.21%

Operating Margin for similar companies or competitors

Company Operating Margin Operating Margin differencediff. Country
Pfizer
PFE
12.60%-48.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
2.78%-88.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
39.47% 60.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
-4.26%-117.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-1,576.98%-6,494.89%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
6.11%-75.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
-662.26%-2,785.56%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
55.68% 125.79%๐Ÿ‡ฌ๐Ÿ‡ง UK

What is a company's Operating Margin?

The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.